DDInter704 DDInter1926
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy [FDA label]. Previously, this drug was indicated only for patients with 17p gene deletion .
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venetoclax
Everolimus {u} (Compound) causes {v} (Side Effect) Feeling abnormal
Feeling abnormal {u} (Side Effect) is caused by {v} (Compound) Secobarbital
Secobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venetoclax
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Secobarbital
Secobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venetoclax
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilonacept
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venetoclax
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Erdafitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venetoclax
Everolimus {u} (Compound) causes {v} (Side Effect) Hepatocellular injury
Hepatocellular injury {u} (Side Effect) is caused by {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Danazol
Danazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venetoclax
Everolimus {u} (Compound) upregulates {v} (Gene) TIPARP
TIPARP {u} (Gene) is upregulated by {v} (Compound) Danazol
Danazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venetoclax
Everolimus {u} (Compound) upregulates {v} (Gene) TIPARP
TIPARP {u} (Gene) is downregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venetoclax
Everolimus {u} (Compound) upregulates {v} (Gene) SERPINA3
SERPINA3 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Nilotinib {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Everolimus (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Secobarbital (Compound) and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib and Erdafitinib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Everolimus (Compound) causes Hepatocellular injury (Side Effect) and Hepatocellular injury (Side Effect) is caused by Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Venetoclax
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Danazol (Compound) and Danazol may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Everolimus (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Danazol (Compound) and Danazol may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Everolimus (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is downregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Everolimus (Compound) upregulates SERPINA3 (Gene) and SERPINA3 (Gene) is upregulated by Nilotinib (Compound) and Nilotinib may lead to a major life threatening interaction when taken with Venetoclax